Full history for every metric is available with a Kvantra account
Evgen Pharma plc (EVG.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -4 | -4 | |||||
| Net profit | £m | -3 | -3 | -3 | -3 | -4 | -3 | -3 |
| EPS reported | £ | -0.01 | -0.01 | |||||
| Operating cashflow per share | £ | -0.01 | -0.01 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.01 | -0.01 | |||||
| Free cash flow | £m | -3 | -3 | |||||
| Net debt | £m | -2 | -2 | |||||
| Book value equity | £m | 2 | 2 | |||||
| Book value per share | £ | 0.01 | 0.01 | |||||
| Number of shares | m | 274.89 | 274.89 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.00 | 1.49 | |||||
| P/S LTM | x | 5.90 | 8.83 | |||||
| P/FCF LTM | x | -0.78 | -1.17 | |||||
| EV/EBITDA LTM | x | -0.09 | -0.42 | |||||
| EV/Sales LTM | x | 0.84 | 3.77 | |||||
| Earnings Yield LTM | % | -134.26% | -139.51% | |||||
| FCF Yield | % | -128.22% | -85.71% | |||||
| Quality | ||||||||
| ROE | % | -134.00% | -81.67% | |||||
| ROIC | % | -134.06% | -134.06% | |||||
| Operating margin | % | -900.51% | -900.51% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -756.57% | -756.57% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -10.41% | -10.41% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.56 | 0.56 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -85.77% | -57.33% | |||||
| Net debt/Equity | x | -0.86 | -0.86 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Evgen Pharma plc (EVG.L)
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free